NovoCure Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
4 analysts have expressed a variety of opinions on NovoCure (NASDAQ:NVCR) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 0 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for NovoCure, presenting an average target of $38.25, a high estimate of $49.00, and a low estimate of $18.00. This current average reflects an increase of 4.79% from the previous average price target of $36.50.
Analyzing Analyst Ratings: A Detailed Breakdown
The standing of NovoCure among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Emily Bodnar | HC Wainwright & Co. | Raises | Buy | $49.00 | $47.00 |
| Emily Bodnar | HC Wainwright & Co. | Raises | Buy | $47.00 | $39.00 |
| David Nierengarten | Wedbush | Maintains | Neutral | $18.00 | $18.00 |
| Emily Bodnar | HC Wainwright & Co. | Lowers | Buy | $39.00 | $42.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to NovoCure. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NovoCure compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of NovoCure's stock. This examination reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of NovoCure's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on NovoCure analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
All You Need to Know About NovoCure
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Financial Insights: NovoCure
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: NovoCure's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 7.81%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: NovoCure's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -22.29%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): NovoCure's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -10.79%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): NovoCure's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -2.86%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: NovoCure's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 2.34.
What Are Analyst Ratings?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.